The Cheapest Ways to Get Semaglutide, Ranked

Every option ranked by monthly price

Ranks 4 and 5 are included for completeness; with NovoCare open to any self-pay patient with a prescription, paying retail list is a $6,000–$10,000 annual mistake.

Tier 1: the copay, if you can get it

Nothing beats $25–$50 a month, $300–$600 a year, for the FDA-approved pen. The problem is access, not price: a large share of commercial plans still exclude weight loss medication in 2026, Medicare does not cover semaglutide for weight loss alone, and covered plans nearly always require prior authorization documenting your BMI, comorbidities, and often previous weight loss attempts.

The ten-minute homework is worth doing before anything else: search your plan's drug formulary for Wegovy, and if it appears, read the prior authorization criteria. The insurance coverage guide walks the process end to end, including what belongs in a medical necessity letter and the Wegovy cardiovascular-indication angle that unlocks some Medicare coverage.

If the formulary says no this year, note when open enrollment opens. Weight loss drug coverage is one of the fastest-moving benefits in employer plans, and a denial in one plan year says nothing about the next. People who set a reminder and re-check annually catch the change; people who treat the first no as permanent can spend years at cash prices a later plan would have covered.

Tier 2: compounded at $99–$299, the cash floor

For everyone whose plan says no, compounded semaglutide is the lowest legitimate cash price. Telehealth programs bundle the provider evaluation, prescription, pharmacy preparation, and shipping into roughly $99–$299 a month, with the spread driven by dose and by how much clinical support is included.

Know what you are buying. Since the FDA declared the semaglutide shortage resolved in February 2025, mass copies under 503A rules are restricted, and legitimate access runs through personalized prescriptions prepared for you specifically. That makes the pharmacy and prescriber behind the price the real product. The compounded vs brand breakdown covers exactly what differs from the pen, and what does not: the active molecule is the same.

Compare programs on what the monthly price includes, because the spread inside the $99–$299 band is mostly inclusions, not medication. The relevant checklist: provider visits and follow-ups, dose adjustments without extra fees, shipping, and syringes. A $149 program charging separately for each follow-up and shipment can cost more over six months than a $199 all-inclusive plan. Ask for the all-in price at your expected maintenance dose, in writing, and compare that figure across programs rather than the advertised entry rate, which is usually the lowest dose with everything unbundled.

Tier 3: $499 for the brand pen, the safe default

NovoCare Pharmacy's $499 flat monthly price for Wegovy or Ozempic at every dose is the cheapest way to get the FDA-approved finished product without insurance. It costs 2–5x the compounded floor, and in exchange you get the original pen device, the manufacturer supply chain, and zero ambiguity about sourcing.

It is the right tier for people who want maximum certainty, whose providers prefer the approved product, or who simply dislike vial-and-syringe administration. At $5,988 a year it is also the benchmark that keeps every other cash price honest: any option costing more needs a reason. Full channel math, including how Ozempic's $998 list fits in, is in the complete semaglutide cost guide.

Timing matters at this tier too: because the $499 rate is flat across doses, it is relatively most attractive at the 2.4 mg maintenance dose, where dose-priced compounded programs sit at the top of their range. Some buyers run the hybrid, compounded during the cheap early titration months, then a switch to brand pens at maintenance once the monthly gap narrows to $200 or less. Any switch belongs in the hands of the prescriber managing your titration, not in a checkout cart.

Red flags when the price looks too good

The bottom of the market attracts operators the top does not. Filters that separate cheap from risky:

• Under ~$99/month all-in: below the realistic cost of licensed pharmacy preparation plus clinical oversight, ask what was cut.
• No prescriber evaluation: legitimate programs require a real intake reviewed by a licensed provider; skip-the-doctor offers fail the most basic test.
• No named, licensed US pharmacy: you should be able to identify who compounds your medication and verify their state license.
• "Research use" or foreign-shipped vials: outside the regulated channel entirely; the savings are not worth the sourcing uncertainty.
• No dose or titration plan: semaglutide titrates from 0.25 mg toward 2.4 mg; a program with no schedule is not practicing medicine.

Eligibility still applies at every tier, BMI 30-plus or 27 with a comorbidity, via the quick assessment. To compare vetted programs at current prices, see today's semaglutide plan pricing here.